arrow
L

Lydia J. Atherton

Centers for Disease Control and Prevention
H指数:7
被引数:311

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In Vitro Study Comparing SARS-CoV-2 Ancestral and Omicron Lineages Sequence & Neutralization Differences

体外研究比较SARS-CoV-2祖先和Omicron谱系序列与中和差异

2025-03-010
OAAI
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
2025-02-010
PRE
The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins

Kumar, S.; Jain, S.; Wali, B.; Zarnitsyna, V.I.; Joshi, D.; Ellis, M.L.; Lai, L.; Malik, A.A.; McPherson, T.O.; Godbole, S.; 等. XBB.1.5 COVID-19疫苗对祖先株和XBB.1.5 SARS-CoV-2刺突蛋白诱导了持久的抗体反应。Sci. Transl. Med. 2025, 17, eadu8067. [Google Scholar] [CrossRef]

2025-01-010
PRE
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024

更新的2023-2024 (单价XBB.1.5) 新型冠状病毒肺炎接种SARS-CoV-2 Omicron XBB和BA.2.86/JN.1的有效性谱系住院和临床严重程度的比较-IVY Network,26家医院,2023年10月18日-2024 3月9日

2024-08-069
OA
Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves

在整个Delta到Omicron波中,美国循环和新兴SARS-CoV-2变体的抗原表征

2024-05-074
OAAI
Evaluation of self-administered antigen testing in a college setting
2022-12-012
OAAI